Mediterranean diet slows Parkinson progression
- Trial ID
- NCT06207136
- Official Title
- Canadian Parkinson's Microbiome Initiative: A Pilot Phase 2 Feasibility Randomized Controlled Trial of the MIND Diet in Parkinson's Disease
- Goal
- Mediterranean diet slows Parkinson progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of British Columbia
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- Parkinson Disease, Diet, Healthy, Gut Microbiome, Gastrointestinal Microbiome
- Interventions
- Mediterranean-style diet
Plain-Language Summary
The goal is to see whether a MIND, Mediterranean-style diet can shift the gut microbiome and lower gut and brain inflammation, with the hope that those changes help motor and non-motor symptoms or slow disease-related decline. Participants are randomly assigned to follow the MIND diet, which emphasizes leafy greens, berries, whole grains, fish, nuts, and olive oil while limiting red meat and sweets, to encourage healthier gut bacteria and reduce inflammatory signals; dopaminergic medications like levodopa are kept stable so any effects can be tied to the diet. About 40 people aged 40 to 80 with a clinical diagnosis of Parkinson's who are cognitively stable, able to attend six visits at UBC and most online sessions in English, and on stable dopaminergic medication are eligible; people with atypical parkinsonism, dementia, recent antibiotic or probiotic use, certain medical conditions such as insulin-treated diabetes or warfarin use, or MRI contraindications are excluded.
Locations
- UBC Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Mediterranean-style diet. The goal is to see whether a MIND, Mediterranean-style diet can shift the gut microbiome and lower gut and brain inflammation, with the hope that those changes help motor and non-motor symptoms or slow disease-related decline. Participants are randomly assigned to follow the MIND diet, which emphasizes leafy greens, berries, whole grains, fish, nuts, and olive oil while limiting red meat and sweets, to encourage healthier gut bacteria and reduce inflammatory signals; dopaminergic medications like levodopa are kept stable so any effects can be tied to the diet. About 40 people aged 40 to 80 with a clinical diagnosis of Parkinson's who are cognitively stable, able to attend six visits at UBC and most online sessions in English, and on stable dopaminergic medication are eligible; people with atypical parkinsonism, dementia, recent antibiotic or probiotic use, certain medical conditions such as insulin-treated diabetes or warfarin use, or MRI contraindications are excluded.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 1 month.